Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

PHASE3RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 18, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2031

Conditions
Residual or Recurrent Grade 2 IDH Mutant Glioma
Interventions
DRUG

Vorasidenib

For oral administration once daily

DRUG

Placebo

For oral administration once daily

Trial Locations (17)

100070

RECRUITING

Tiantan Hospital, Beijing

200040

RECRUITING

Huashan Hospital Fudan University, Shanghai

Unknown

RECRUITING

The Second People's Hospital of Shenzhen, Shenzhen

RECRUITING

West China Hospital Sichuan University, Chengdu

NOT_YET_RECRUITING

Bejing Tsinghua Changgung Hospital, Beijing

NOT_YET_RECRUITING

Cancer Hospital Chinese Academy of Medical Science, Beijing

NOT_YET_RECRUITING

Peking Union Medical College Hospital, Beijing

RECRUITING

Sanbo Brain Hospital, Capital Medical University, Beijing

NOT_YET_RECRUITING

Xuanwu Hospital Capital Medial University, Beijing

NOT_YET_RECRUITING

The First Affilated Hospital of Fujian Medical University, Fuzhou

NOT_YET_RECRUITING

SUN Yat-Sen University Cancer Center, Guangzhou

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Harbin

NOT_YET_RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

RECRUITING

The Second Affiliated Hospital of Air Force Military Medical University, Xi'an

NOT_YET_RECRUITING

The Affiliated Hospital of Xuzhou Medical Hospital, Xuzhou

NOT_YET_RECRUITING

Taipei Veterans General Hospital, Taipei

NOT_YET_RECRUITING

Chang Gung Memorial Hospital,, Taoyuan District

All Listed Sponsors
lead

Servier

INDUSTRY